3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Completed
2
Terminated
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
1
Lymphoid
1
Head & Neck
1
Genitourinary
1
Dermatologic
1
Breast
1
Conditions
Urologic Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Neoplasms
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Adenoid Cystic
1
Breast Neoplasms
1
Interventions
Cyclophosphamide
1492
Cisplatin
1413
Paclitaxel
1316
Radiotherapy
1261
Carboplatin
1249
Gemcitabine
1215
Docetaxel
1109
Bevacizumab
1030
Fluorouracil
894
Doxorubicin
792
Dexamethasone
748
Rituximab
719
Capecitabine
716
Oxaliplatin
700
Etoposide
678
pembrolizumab
677
Irinotecan
634
Filgrastim
621
Cytarabine
586
Leucovorin
579
Nivolumab
558
Vincristine
515
Prednisone
475
Cetuximab
465
Bortezomib
459
Erlotinib Hydrochloride
456
Trastuzumab
447
Methotrexate
438
Lenalidomide
427
Pemetrexed
419
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Completed
×
Interventional
×
GSK-3326595
×
Clear all
NCT02783300
2025-03-10
Meteor 1
GlaxoSmithKline
Phase 1
Completed
297 enrolled
76 charts
NCT04676516
2022-10-25
OTT-19-06
Ottawa Hospital Research Institute
Phase 2
Completed
40 enrolled